Veracity Forensics Adds 2 Industry Veterans to Its Team

Clint Modesitt has joined on as director of forensic investigations and Jared Weaver has come aboard as a forensic consultant at Veracity Forensics, a Flower Mound-based digital forensics and discovery services company.

Flower Mound-based Veracity Forensics, a national provider of digital forensic investigation and discovery services, announced that Clint Modesitt has joined the company as director of forensic investigations and Jared Weaver has come aboard as a forensic consultant.

The firm said the additions reinforce Veracity Forensics’ commitment to meeting the increasing demand for its services to law firms, corporations, and eDiscovery vendors.

“We’re thrilled to welcome Clint Modesitt and Jared Weaver to our expanding team,” CEO Chip Koons said in a statement. “Their expertise and passion for the truth align perfectly with our company motto, ‘Seek The Truth—Protect What Matters.’ With their addition, we’re even better equipped to meet the diverse needs of our clients and provide them with the highest level of service.”

An industry leader in digital forensics, Veracity Forensics said it is dedicated to delivering reliable, accurate, and comprehensive solutions to clients who require digital forensic investigation, expert witness testimony, and discovery services.

Its core services encompass the forensic analysis of computers, mobile devices, cloud applications, audio and video recordings, as well as the collection and preservation of electronic evidence of any kind and expert witness testimony.

The company said that Modesitt assumes a strategic leadership position. He has more than 22 years of industry experience in digital forensics and investigation management, and will provide valuable insights, lead forensic examinations, and serve as an expert witness.

He will oversee and manage lab operations, ensuring the highest standards of quality and efficiency, the company said.

Weaver will be responsible for client-facing consulting, client development and retention, and serving as a senior forensic analyst within the lab.

He has more than nine years’ experience and brings a deep understanding of client needs and a proven track record in delivering exceptional results, the company said.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.  

R E A D   N E X T

  • Digital Edition: Dallas Innovates Magazine 2023

    Welcome to the pulse of North Texas, where creativity and innovation converge to shape the future of business and beyond.

  • Up to 42% of Dallas households lack a fixed connection to the internet. Without the tools and know-how to connect to the digital world, people can be left behind, especially in economically disadvantaged parts of the city. DIA is working to change that with its Digital Ambassador program. Now, with help from the Dallas Foundation and Santander Consumer USA—and a $1 million grant from AT&T—DIA aims to get people not just connected, but thriving.

  • Hundreds packed the Granada theater to watch the gloves-off "fights" to cap off Dallas Startup Week. Tech types duked it out verbally amid cheering, hooting, and generally raucous reactions from the audience. Check out what you missed—or relive it here.

  • Dallas-based unicorn o9 Solutions is using its Digital Brain technology to predict weather patterns, transportation hiccups, and employment fluctuations months before problems occur. Then its digital twin technology can recommend solutions. CEO Chakri Gottemukkala says o9's new Supply Sensing tool applies longstanding methods to "predicting and steering clear of future supply disruptions."

  • The Coppell-based startup said it will use the proceeds to advance and scale its Digital Medical Home, which includes diagnostic-enabled Virtual Primary Care and Virtual Behavioral Health Solutions tailored to fit the healthcare needs of any population. Recuro integrates advanced science, data, at-home diagnostics, and targeted genomics for cancer screening and pharmacogenomics "to better inform integrated care," the company says.